TY - JOUR
T1 - Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort
T2 - Role of dopamine, serotonin and glutamate candidate genes
AU - PEPs Group
AU - Mas, S.
AU - Gassó, P.
AU - Lafuente, A.
AU - Bioque, M.
AU - Lobo, A.
AU - Gonzàlez-Pinto, A.
AU - Olmeda, M. S.
AU - Corripio, I.
AU - Llerena, A.
AU - Cabrera, B.
AU - Saiz-Ruiz, J.
AU - Bernardo, M.
AU - Mezquida, Gisela
AU - Meseguer, Ana
AU - Bernardo, Enrique García
AU - Parellada, Mara
AU - Alonso-Solís, Anna
AU - Grasa, Eva
AU - Hernandez, Miryam
AU - Cengotitabengoa, Monica Martinez
AU - Barcones, Fe
AU - Arbej, Julio
AU - Sanjuan, Julio
AU - Aguilar, Eduardo J.
AU - Balbuena, Antonio
AU - Mané, Anna
AU - Torrent, Carla
AU - Vieta, Eduard
AU - Baeza, Immaculada
AU - de la Serna, Elena
AU - Contreras, Fernando
AU - Albacete, Auria
AU - García-Portilla, Maria Paz
AU - Bobes, Julio
AU - Rabadán, Arantzazu Zabala
AU - Echevarría, Rafael Segarra
AU - Morales-Muñoz, Isabel
AU - Rodriguez-Jimenez, Roberto
AU - Butjosa, Anna
AU - Rodie, Judith Usall
AU - Sarró, Salvador
AU - Landín-Romero, Ramón
AU - Cuadrado, Angela Ibañez
AU - Cuesta, Manuel J.
AU - Balanzá-Martínez, Vicent
N1 - Publisher Copyright:
© 2016 Macmillan Publishers Limited, part of Springer Nature.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two hundred and two SNPs in 31 candidate genes (involved in dopamine, serotonin and glutamate pathways) were analyzed in the present study. One hundred and thirteen FEP patients (43 presenting EPS and 70 non-presenting EPS) treated with high-potency AP (amisulpride, paliperidone, risperidone and ziprasidone) were included in the analysis. The statistical analysis was adjusted by age, gender, AP dosage, AP combinations and concomitant treatments as covariates. Four SNPs in different genes (DRD2, SLC18A2, HTR2A and GRIK3) contributed significantly to the risk of EPS after correction for multiple testing (P<1 × 10 -4). These findings support the involvement of dopamine, serotonin and glutamate pathways in AP-induced EPS.
AB - This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two hundred and two SNPs in 31 candidate genes (involved in dopamine, serotonin and glutamate pathways) were analyzed in the present study. One hundred and thirteen FEP patients (43 presenting EPS and 70 non-presenting EPS) treated with high-potency AP (amisulpride, paliperidone, risperidone and ziprasidone) were included in the analysis. The statistical analysis was adjusted by age, gender, AP dosage, AP combinations and concomitant treatments as covariates. Four SNPs in different genes (DRD2, SLC18A2, HTR2A and GRIK3) contributed significantly to the risk of EPS after correction for multiple testing (P<1 × 10 -4). These findings support the involvement of dopamine, serotonin and glutamate pathways in AP-induced EPS.
UR - https://www.scopus.com/pages/publications/84976330756
U2 - 10.1038/tpj.2016.44
DO - 10.1038/tpj.2016.44
M3 - Article
C2 - 27272046
AN - SCOPUS:84976330756
SN - 1470-269X
VL - 16
SP - 439
EP - 445
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
IS - 5
ER -